Bank of America Reinstates Diplomat Pharmacy Inc to Neutral

Brokerage firm Bank of America Reinstates its rating on Diplomat Pharmacy Inc(NYSE:DPLO). The shares have been rated Neutral. The rating by Bank of America was issued on Jun 7, 2016.

In a different note, Avondale Partners said it Initiates Coverage on Diplomat Pharmacy Inc, according to a research note issued on Apr 18, 2016. The shares have been rated ‘Market Outperform’ by the firm. Credit Suisse said it Initiates Coverage on Diplomat Pharmacy Inc, according to a research note issued on Mar 15, 2016. The shares have been rated ‘Neutral’ by the firm.

Diplomat Pharmacy Inc (DPLO) shares turned negative on Fridays trading session with the shares closing down -0.67 points or -1.96% at a volume of 2,59,077. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $34.44. The peak price level was also seen at $34.44 while the days lowest was $33.15. Finally the shares closed at $33.51. The 52-week high of the shares is $52.3324 while the 52-week low is $22.41. According to the latest information available, the market cap of the company is $2,211 M.

Diplomat Pharmacy Inc(DPLO) last announced its earnings results on May 9, 2016 for Fiscal Year 2016 and Q1.Company reported revenue of $995.87M. Analysts had an estimated revenue of $982.87M. Earnings per share were $0.23. Analysts had estimated an EPS of $0.18.

Several Insider Transactions has been reported to the SEC. On Jun 2, 2016, Atheer A Kaddis (EVP of Sales & Strategic Align) sold 12,325 shares at $32.37 per share price.Also, On Dec 8, 2015, Philip R Hagerman (Chairman and CEO) sold 2,300,000 shares at $33.60 per share price.On Dec 2, 2015, Gary W Kadlec (President) sold 30,000 shares at $35.08 per share price, according to the Form-4 filing with the securities and exchange commission.

Diplomat Pharmacy Inc. (Diplomat) is an independent specialty pharmacy in the United States. The Company provides specialty pharmacy support services to a national network of retailers and independent pharmacy groups hospitals and health systems. The Company offers services in Specialty Drug Dispensing which includes its specialty infusion pharmacy services. The specialty drug dispensing services include Patient Care Coordination Clinical Services Compliance and Persistency Programs Patient Financial Assistance Specialty Pharmacy Training/Consulting (Diplomat University) Benefits Investigation Prior Authorization Risk Evaluation and Medication Strategy (REMS) Retail Specialty Services Hospital and Health System Services and Hub Services. The Company help patients adhere to complicated medication therapies process refills and manage any side effects and insurance concerns to ensure they get the standard of care.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Diplomat Pharmacy Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Diplomat Pharmacy Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.